ALLO - Allogene's ALLO-501A for lymphoma gets regenerative medicine advanced therapy designation

Allogene Therapeutics (NASDAQ:ALLO) on Wednesday said that the U.S. FDA had granted a regenerative medicine advanced therapy (RMAT) designation to its investigational product ALLO-501A for the treatment of large B-cell lymphoma, a type of cancer in white blood cells called lymphocytes. The FDA's RMAT designation is given to regenerative medicines, such as a cell therapy, that can treat or cure a serious or life-threatening disease or condition. ALLO said that the RMAT designation for ALLO-501A was based on the potential of the product to address the unmet need for patients who have failed other therapies. The company said it intends to start a phase 2 trial with ALLO-501A in mid-2022. ALLO stock +2.6% to $9.74 in premarket trading.

For further details see:

Allogene's ALLO-501A for lymphoma gets regenerative medicine advanced therapy designation